loader2
Login Open ICICI 3-in-1 Account

Thyrocare Technologies Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Thyrocare Technologies Ltd. 14 Oct 2025 17:50 PM

Q2FY26 Quarterly Result Announced for Thyrocare Technologies Ltd.

Healthcare Services company Thyrocare Technologies announced Q2FY26 results

  • Consolidated revenue of Rs 216.53 crore, registering a strong 22% YoY growth.
  • EBITDA rose sharply by 49% YoY to Rs 75.36 crore.
  • EBITDA margin of 33% for Q2FY26.
  • Profit After Tax surged 82% YoY to Rs 47.90 crore.
  • PAT Margin: 22% for Q2FY26.
  • Board of Directors has declared an interim dividend of Rs 7 per equity share (of Rs 10 face value each, pre-bonus) with 24-October-2025 as the record date, and approved a bonus issue in the ratio of 2:1, subject to statutory, regulatory, and shareholder approval.

Rahul Guha, MD & CEO, Thyrocare Technologies, said: “We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and valuedriven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India”

Alok Kumar, Jagnani Group CFO, said: “We are delighted with Thyrocare’s strong Q2FY26 performance, which reflects the strength of our business fundamentals, disciplined financial management, and the unwavering commitment of our teams. As we mark 25 years of trust and innovation, the bonus share announcement underscores our commitment to our shareholders and investors, and reinforces confidence in our long-term growth journey”.

Result PDF

Healthcare Services company Thyrocare Technologies announced Q1FY26 results

Q1FY26 Financial Highlights:

  • Revenue from operations: Rs 193.03 crore compared to Rs 156.91 crore during Q1FY25, change 23%.
  • EBITDA: Rs 57.46 crore compared to Rs 42.01 crore during Q1FY25, change 37%
  • EBITDA Margin: 30% for Q1FY26.
  • PAT: Rs 38.06 crore compared to Rs 23.47 crore during Q1FY25, change 62%.
  • PAT Margin: 20% for Q1FY26.

Business Highlights:

  • Pathology Business - Franchise revenue grew by 20% YoY, while partnership revenue surged by 36% YoY.
  • Total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase.
  • Opened New Labs in Bhagalpur, Kashmir and Roorkee.

Result PDF

Healthcare Services company Thyrocare Technologies announced Q4FY25 results

  • Consolidated revenue: Rs 187.2 crore compared to Rs 154.2 crore during Q4FY24, change 21% YoY with Pathology and Radiology segments growing by 23% YoY and 7% YoY respectively.
  • PAT: Rs 21.3 crore compared to Rs 17.2 crore during Q4FY24, change 24%.
  • Reported EBITDA: Rs 57.4 crore compared to Rs 33.8 crore during Q4FY24, change 70%.
  • Total volume in FY25 grew to 167.9 million, largest by far on volume.
  • Revenue from franchise surged by 22% YoY, and partnership revenue saw 24% YoY growth.
  • Consolidated gross margin stood at 74%, and normalized EBITDA margin was 35%.
  • Standalone normalized EBITDA grew by 72% YoY, while PAT* increased by 72% YoY.
  • Consolidated normalized EBITDA grew by 78% YoY, while PAT* increased by 88% YoY.
  • Recommended a final dividend of Rs 21 per equity share subject to the approval of shareholders at the ensuing shareholders meeting.
  • Consolidated cash reserves as of March 2025 is Rs 191.8 crore.
  • Opened new labs in Bhagalpur and Kashmir.

Result PDF

Healthcare Services company Thyrocare Technologies announced Q3FY25 results

  • Revenue: Rs 165.9 crore, compared to Rs 134.7 crore during Q3FY24, change 23% YoY.
  • EBITDA: Rs 41.6 crore, compared to Rs 31.6 crore during Q3FY24, change 32% YoY.
  • Consolidated gross margin stood at 73%, and normalized EBITDA margin was 30%
  • PAT: Rs 18.9 crore, compared to Rs 14.6 crore during Q3FY24 30% YoY
  • Pathology and Radiology segments grew by 24% YoY and 13% YoY respectively

Result PDF

Healthcare Services company Thyrocare Technologies announced Q2FY25 results

Financial Highlights:

  • Consolidated Revenue increased by 20% year-over-year (YoY) with Pathology and Radiology segments growing by 20% YoY and 21% YoY respectively.
  • Revenue from partnerships surged by 33% YoY, and franchise revenue saw 14% YoY growth.
  • Consolidated gross margin stood at 71%, and normalized EBITDA margin was 29%.
  • Standalone reported EBITDA grew by 33% YoY, while PAT increased by 45% YoY.
  • Consolidated reported EBITDA grew by 28% YoY, while PAT increased by 29% YoY

Business Highlights:

  • Opened 2 new labs in Madurai and Surat.
  • 28 NABL accredited labs at present out of 32 labs including Tanzania.
  • 96% of our sample load is processed in NABL labs.
  • Completed the acquisition of Polo Labs on July 29, 2024.
  • Signed the Business Transfer Agreement to acquire the clinical diagnostic business of Vimta Labs on August 30, 2024, and completed the acquisition on October 11, 2024.

Result PDF

Healthcare Services firm Thyrocare Technologies declares Q4FY22 result:

  • Revenue from operations of Rs. 562 Crore, grown by 18% YoY. Revenue for the final quarter of the year of Rs. 123 Crore, grown by 12% in sequential quarters mainly with revival of the base non covid business. Revenue from COVID business was flat in sequential quarters despite of 3rd wave in January. Non Covid business however revived significantly and surpassed the pre-COVID business. Continued focus on B2B business enabled us to garner lost volumes. Revenue and volumes for the month of March were all time high
  • Gross margin for the year improved mainly on account of reduction in the covid reagent/ consumables, however to enable growth aggressive prices are offered in the last quarter on routine non aarogyam tests and certain aarogyam profiles that has lead to impact on Q4 gross margins which shall settle down in the coming period.
  • Absolute EBITDA of Rs. 231 crore, grown by 35% YoY, mainly on account of better EBITDA margins on account of lower reagent/ consumable and operations cost in Government COVID business. The EBITDA margin at 41% for the year were tampered down in the last two quarters mainly on account of impact on the topline due to erosion of high margin government contract business, aggressive discounts to the network on some routine tests/ profiles to revive the business, spendings on manpower in particular growth teams to sustain growth and infrastructure to improve turnaround time to the patients.
  • 4.40 million COVID RTPCR tests were performed in the year, though despite 3 rd wave in January only 0.41 million were performed in the last quarter, thereby the focus is now shifted to non COVID segment.
  • Total 21.07 million samples (including COVID) sourced from 16.32 million patients (including COVID) were processed during current year.
  • 110.30 million tests were processed in the current year that includes standalone tests, COVID tests and tests included in the preventive care Aarogyam profiles.
  • Pathology business grew by 12% in sequential quarter and yearly by 18%. Growth in the current quarter was mainly on account of revival of B2B non COVID business
  • Radiology business accounted for about 5% of reported consolidated revenue of Thyrocare Group revived significantly after complete shut down for couple of months in covid and thereafter out of the impact of lockdowns, posting 34% YOY growth in the current year
  • Consolidated annual revenue of the group grew by 19% YOY, with positive signs of revival in non covid business. COVID business significantly eroded in last two quarters and radiology business growing at pre COVID level.

 

 

 

Result PDF

Healthcare Services firm Thyrocare Technologies declares Q3FY22 result:

  • Revenue from operations of Rs. 110 Crore, significantly impacted due to erosion of Revenue from government business in the earlier period, festivities and general fall in demand historically evidenced in Q3.
    • Revenue from Government contracts alone dipped by 82% QoQ, due to reduction in spending on Covid and onetime Govt. projects.
    • Revenue for nine months ended 31 December 2021 of Rs. 438 Crore grew by 31 % YOY, due to one time government projects executed in earlier quarters.
    • Non Covid business continued to be at par pre-Covid level. The per sample and per patient realization continued to improve across all the segments.
  • Gross margin improved YOY and sustained at sequential quarter. The hiring at the managerial level is ramped up to ensure business growth in all verticals in the coming years.
  • EBITDA margin staggered mainly on account of impact on the topline due to erosion of government contract business, fixed costs of personnel and other operational costs.
    • Other expenses during the quarter includes CSR expenses Rs. 1.92 crore (Q2- Rs. 0.49 Crore) incurred during the period.
  • Only 0.40 million Covid RTPCR performed (2.13 million in previous quarter) significantly impacting the performance of current quarter.
  • 4.06 million (Q2 - 6.40 million) samples sourced from 3.00 million (Q2 - 5.29 million) patients were processed during current quarter of which about 3.62 million (Q2 - 4.19 million) samples were for non – Covid related tests/ parameters.
  • 24.22 million (Q2 - 28.28 million) tests were processed in the current quarter that includes standalone tests and tests included in the preventive care Aarogyam profiles.

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app